Evidence map›Paper›PMID 23650357›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2013

Combined effect of a peptide-morpholino oligonucleotide conjugate and a cell-penetrating peptide as an antibiotic.

Donna Wesolowski, Dulce Alonso, Sidney Altman

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Antisense antimicrobial therapeutics.Current opinion in microbiology · 2016
    Review
  13. Review
  14. Targeting protein translation, RNA splicing, and degradation by morpholino-based conjugates in Plasmodium falciparum.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Donna WesolowskiDepartment of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06520, USA.
Dulce Alonso
Sidney Altman
Yale University · US

Funding

IMMUNOPATHOGENESIS OF MYCOBACTERIUM AVIUM DISEASER01AI041922 · NIAID · TRUDEAU INSTITUTE, INC. · PI COOPER, ANDREA M · 1997 to 2001
$512k
NIAID NIH HHS R01AI041922-11A2
6 · The paper itself

Abstract

A cell-penetrating peptide (CPP)-morpholino oligonucleotide (MO) conjugate (PMO) that has an antibiotic effect in culture had some contaminating CPPs in earlier preparations. The mixed conjugate had gene-specific and gene-nonspecific effects. An improved purification procedure separates the PMO from the free CPP and MO. The gene-specific effects are a result of the PMO, and the nonspecific effects are a result of the unlinked, unreacted CPP. The PMO and the CPP can be mixed together, as has been shown previously in earlier experiments, and have a combined effect as an antibiotic. Kinetic analysis of these effects confirm this observation. The effect of the CPP is bacteriostatic. The effect of the PMO appears to be bacteriocidal. An assay for mutations that would alter the ability of these agents to affect bacterial viability is negative.

Indexed as

Anti-Bacterial AgentsCell-Penetrating PeptidesMorpholinosBacteriaBacterial InfectionsAnti-Bacterial AgentsCell-Penetrating PeptidesMorpholinosEGS technologygram-negative bacteriagram-positive bacteriaRNase P

Identifiers

PMID23650357
PMCPMC3666680
OpenAlexW2152496822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.